EFFECT OF ORAL ACTIVATED-CHARCOAL ON PROPRANOLOL PHARMACOKINETICS FOLLOWING INTRAVENOUS ADMINISTRATION TO RABBITS

被引:4
|
作者
ALMESHAL, MA
ELSAYED, YM
ALANGARY, AA
ALDARDIRI, MM
机构
[1] Department of Pharmaceutics, College of Pharmacy, KingSaud University, Riyadh, 11451
关键词
D O I
10.1111/j.1365-2710.1993.tb00564.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics of propranolol following intravenous administration (1 mg/kg), with and without treatment with oral activated charcoal, was investigated in rabbits. In charcoal-treated rabbits a significant reduction in propranolol serum concentrations was observed compared to control animals. Charcoal treatment significantly reduced the half-life of elimination (16.6%) and the mean residence time (19%) of propranolol. A 17% increase in the systemic clearance and a 14% decrease in AUC were also noted. Charcoal administration did not significantly alter the volume of distribution (V(c), V(area) and V(SS)) or the apparent distribution half-life. A two-compartment model adequately described propranolol in control and treated rabbits. The results indicate that administration of oral activated charcoal enhances the systemic elimination of propranolol. This is presumably mediated by interruption of the enterohepatic circulation of propranolol by activated charcoal.
引用
收藏
页码:39 / 44
页数:6
相关论文
共 50 条
  • [41] SUCCESSFUL TREATMENT OF DIGITOXIN OVERDOSE BY REPEATED ORAL-ADMINISTRATION OF ACTIVATED-CHARCOAL
    HANSEN, D
    JACOBS, M
    POND, S
    MARKS, J
    GARNER, J
    GOLDSCHLAGER, N
    VETERINARY AND HUMAN TOXICOLOGY, 1981, 23 (05) : 353 - 353
  • [42] ORAL ACTIVATED-CHARCOAL IN PATIENTS WITH UREMIC PRURITUS
    GIOVANNETTI, S
    BARSOTTI, G
    CUPISTI, A
    DANI, L
    BANDINI, S
    ANGELINI, D
    ANTONELLI, A
    SALVADORI, M
    URTI, DA
    NEPHRON, 1995, 70 (02): : 193 - 196
  • [43] TREATMENT OF THEOPHYLLINE TOXICITY WITH ORAL ACTIVATED-CHARCOAL
    TRUE, RJ
    BERMAN, JM
    MAHUTTE, CK
    CRITICAL CARE MEDICINE, 1984, 12 (02) : 113 - 114
  • [44] FATAL PULMONARY ASPIRATION OF ORAL ACTIVATED-CHARCOAL
    POWER, KJ
    BRITISH MEDICAL JOURNAL, 1988, 297 (6653): : 919 - 919
  • [45] ENHANCEMENT OF THEOPHYLLINE CLEARANCE BY ORAL ACTIVATED-CHARCOAL
    BERLINGER, WG
    SPECTOR, R
    GOLDBERG, MJ
    JOHNSON, GF
    QUEE, CK
    BERG, MJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (03) : 351 - 354
  • [46] PRESERVING THE EMETIC EFFECT OF SYRUP OF IPECAC WITH CONCURRENT ACTIVATED-CHARCOAL ADMINISTRATION
    KRENZELOK, EP
    PASTERNAK, S
    FREEDMAN, G
    VETERINARY AND HUMAN TOXICOLOGY, 1985, 27 (04) : 310 - 310
  • [47] ENHANCEMENT OF THEOPHYLLINE CLEARANCE BY ORAL ACTIVATED-CHARCOAL
    BERLINGER, WG
    SPECTOR, R
    GOLDBERG, MJ
    JOHNSON, GF
    QUEE, CK
    BERG, MJ
    CLINICAL RESEARCH, 1982, 30 (04): : A763 - A763
  • [48] EFFECTS OF ACTIVATED-CHARCOAL ON THE PHARMACOKINETICS AND TOXICITY OF CISPLATIN (CDDP)
    FEUN, LG
    SAVARAJ, N
    LU, K
    WANG, DC
    ROBBINS, VW
    STEVENS, LC
    FIELDS, WS
    LOO, TL
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 263 - 263
  • [49] SIMULATED ACETAMINOPHEN OVERDOSE - PHARMACOKINETICS AND EFFECTIVENESS OF ACTIVATED-CHARCOAL
    ROSE, SR
    GORMAN, RL
    ODERDA, GM
    KLEINSCHWARTZ, W
    WATSON, WA
    ANNALS OF EMERGENCY MEDICINE, 1991, 20 (10) : 1064 - 1068
  • [50] ORAL ACTIVATED-CHARCOAL - NEW HYPOLIPIDEMIC AGENT
    LUM, G
    MANIS, T
    ZEIG, S
    FRIEDMAN, EA
    CLINICAL CHEMISTRY, 1978, 24 (06) : 1045 - 1045